Celyad participating in Large and Midcap Event in Paris
(Thomson Reuters ONE) -
Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ:
CYAD), a leader in the discovery and development of engineered cell therapies,
announces its participation in the 15th edition of the European Large & Midcap
Event, which will be held in Paris this coming October 7th and 8th.
By participating in this event focusing especially on European midcap companies,
Celyad is seizing the opportunity to share its strategy and present its
main development programmes to European institutional investors and analysts.
Patrick Jeanmart, Administrative and Financial Director of Celyad, comments: "We
are delighted to be participating once again in the Large and Midcap Event. For
two years, Celyad has been developing firm ties with European institutional
investors. This event is ideal for sharing with them the major advances our
company has achieved in recent months in our cardiology and oncology
programmes".
***END***
For more information, please contact:
-------------------------------------------------------------------------------
For Europe : Consilium Strategic Communications
Amber Fennell, Chris Gardner, Chris Welsh, and Laura Thornton - T: +44 (0)20
3709 5700 - celyad(at)consilium-comms.com
-------------------------------------------------------------------------------
For the U.S. : The Ruth Group
Lee Roth (Investors), and Kirsten Thomas (Media) - T: +1 646 536 7012 / 7014 -
celyad(at)theruthgroup.com
-------------------------------------------------------------------------------
For France : NewCap
Pierre Laurent and Nicolas Mérigeau - T: + 33(0)1 44 71 94 94 -
celyad(at)newcap.fr
-------------------------------------------------------------------------------
Celyad
Christian Homsy, CEO and Patrick Jeanmart, Chief Financial Officer : T: +32
(0)10 39 41 00 - investors(at)celyad.com
-------------------------------------------------------------------------------
To subscribe to Celyad's newsletter, visit www.celyad.com
Follow us on Twitter (at)CelyadSA
-------------------------------------------------------------------------------
About Celyad
Founded in 2007, and based in Belgium, Celyad is a leader in engineered cell
therapy with clinical programs initially targeting indications in cardiology and
oncology. Celyad is developing its lead cardiovascular disease product
candidate, C- Cure®, for the treatment of ischemic heart failure, and has
completed enrollment of a Phase III trial in Europe and Israel. In addition, the
Company is developing a novel portfolio of CAR T-cell therapies that utilize
human Natural Killer cell receptors for the treatment of numerous blood and
solid cancers. Its lead oncology product candidate, NKG2D CAR T-cell, entered a
Phase I clinical trial in April 2015.
Celyad's ordinary shares are listed on Euronext Brussels and Euronext Paris
under the ticker symbol CYAD and Celyad's American Depositary Shares are listed
on the NASDAQ Global Market under the ticker symbol CYAD.
To learn more about Celyad, please visit www.celyad.com
Forward looking statements
In addition to historical facts or statements of current condition, this press
release contains forward-looking statements, including statements about the
safety and efficacy of Celyad's product candidates, the potential clinical and
commercial potential of these product candidates and the adequacy of Celyad's
financial resources, which reflect our current expectations and projections
about future events, and involve certain known and unknown risks, uncertainties
and assumptions that could cause actual results or events to differ materially
from those expressed or implied by the forward- looking statements. These
forward-looking statements are further qualified by important factors, which
could cause actual results to differ materially from those in the forward-
looking statements, including risks associated with conducting clinical trials;
the risk that DSMB's determination not to discontinue the Phase III clinical
trials for C-Cure® on the basis of non- futility is not a determination as to
the likelihood of success and is not a guarantee that the trial will be
successful; the risk that safety, bioactivity and efficacy demonstrated in
earlier clinical or pre-clinical studies may not be replicated in subsequent
studies; risk associated with the timely submission and approval of anticipated
regulatory filings; the successful initiation and completion of clinical trials,
including Phase III clinical trials for C-Cure® and Phase I clinical trial for
NKG2D CAR T-cell; risks associated with the satisfaction of regulatory and other
requirements; risks associated with the actions of regulatory bodies and other
governmental authorities; risks associated with obtaining, maintaining and
protecting intellectual property, our ability to enforce our patents against
infringers and defend our patent portfolio against challenges from third
parties; risks associated with competition from others developing products for
similar uses; risks associated with our ability to manage operating expenses;,
and risks associated with our ability to obtain additional funding to support
our business activities and establish and maintain strategic business alliances
and business initiatives. A further list and description of these risks,
uncertainties and other risks can be found in the Company's Securities and
Exchange Commission filings and reports, including in the Company's prospectus
filed with the SEC on June 19, 2015 and future filings and reports by the
Company. Given these uncertainties, the reader is advised not to place any undue
reliance on such forward-looking statements. These forward-looking statements
speak only as of the date of publication of this document. The Company expressly
disclaims any obligation to update any such forward-looking statements in this
document to reflect any change in its expectations with regard thereto or any
change in events, conditions or circumstances on which any such statement is
based, unless required by law or regulation.
C3BS-CQR-1, C-Cure, NKG2D CAR T-cell, C-Cathez, OnCyte, Celyad, Cardio3
BioSciences and the Cardio3 BioSciences, Celyad, C-Cathez, CHART-1, CHART-2 and
OnCyte logos are signs internationally protected under applicable Intellectual
Property Laws. Mayo Clinic holds equity in Celyad as a result of intellectual
property licensed to the Company.
Press release (PDF):
http://hugin.info/171278/R/1956522/712657.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: CELYAD S.A. via GlobeNewswire
[HUG#1956522]
Unternehmensinformation / Kurzprofil:
Datum: 02.10.2015 - 19:04 Uhr
Sprache: Deutsch
News-ID 424433
Anzahl Zeichen: 7961
contact information:
Town:
Mont-Saint-Guibert
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 168 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Celyad participating in Large and Midcap Event in Paris"
steht unter der journalistisch-redaktionellen Verantwortung von
CELYAD S.A. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
